Evidence map›Paper›PMID 19671448›Full record

ArticleInternational immunopharmacology2009

Polysaccharides derived from Yamoa (Funtumia elastica) prime gammadelta T cells in vitro and enhance innate immune responses in vivo.

Jill C Graff, Emily M Kimmel, Brett Freedman, Igor A Schepetkin, Jeff Holderness, Mark T Quinn, Mark A Jutila, Jodi F Hedges

Open access · greenAbstract readComparative Study
In one paragraph

Article in International immunopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Immunomodulatory Effects ofMolecules (Basel, Switzerland) · 2020
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jill C GraffVeterinary Molecular Biology, Montana State University, Bozeman, MT 59718, USA.
Emily M Kimmel
Brett Freedman
Igor A Schepetkin
Jeff Holderness
Mark T Quinn
Mark A Jutila
Jodi F Hedges
Montana State University · US

Funding

VIRUSES: FROM PARTICLES TO PROTEOMICSP20RR020185 · NCRR · MONTANA STATE UNIVERSITY - BOZEMAN · PI QUINN, MARK T · 2004 to 2011
$17.0M
CAMs as counter measures against infectious and inflammatory diseaseP01AT004986 · NCCIH · MONTANA STATE UNIVERSITY - BOZEMAN · PI JUTILA, MARK A · 2008 to 2012
$5.9M
Pilot Grants ProgramP30GM110732 · NIGMS · MONTANA STATE UNIVERSITY - BOZEMAN · PI QUINN, MARK T · 2014 to 2018
$5.4M
NCCIH NIH HHS AT0004986-01NCCIH NIH HHS P01 AT004986NCRR NIH HHS P20 RR020185NIAID NIH HHS N01 AI040009NIAID NIH HHS N01-AI-40009NIGMS NIH HHS P30 GM110732
6 · The paper itself

Abstract

Yamoa (ground bark of Funtumia elastica tree) is marketed and sold as a dietary supplement with anecdotal therapeutic effects in the treatment of asthma and hay fever. We determined that Yamoa and Yamoa-derived polysaccharides affected innate immunity, in part, by priming gammadelta T cells. Gene expression patterns in purified bovine gammadelta T cells and monocytes induced by Yamoa were similar to those induced by ultrapure lipopolysaccharide (uLPS). In the presence of accessory cells, Yamoa had priming effects that were similar to those of LPS on bovine and murine gammadelta T cells, but much more potent than LPS on human gammadelta T cells. The bioactive component of Yamoa was delineated to a complex polysaccharide fraction (Yam-I). Intraperitoneal injection of Yamoa and Yam-I in mice induced rapid increases in peritoneal neutrophils directed by changes in chemokine expression. In support of a unique agonist found in Yam-I, similar peritonitis responses were also observed in TLR4- and MyD88-deficient mice. Therapeutic treatment with Yam-I resulted in decreased bacterial counts in feces from mice with Salmonella enterica serotype typhimurium (ST)-induced enterocolitis. This characterization of the immune stimulatory properties of polysaccharides derived from Yamoa suggests mechanisms for the anecdotal positive effects of its ingestion and that these polysaccharides show potential for application in innate protection from disease.

Indexed as

AnimalsCattleEnterocolitisGene Expression ProfilingHumansImmunity, InnateLipopolysaccharidesMiceMice, Inbred BALB CMyeloid Differentiation Factor 88Neutrophil InfiltrationPlant ExtractsPolysaccharidesSalmonella InfectionsSalmonella typhimuriumT-Lymphocyte SubsetsLipopolysaccharidesMYD88 protein, humanMyeloid Differentiation Factor 88Plant ExtractsPolysaccharidesToll-Like Receptor 4yamoa

Identifiers

PMID19671448
PMCPMC2749908
OpenAlexW2012045915

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.